Quote | PLUS THERAPEUTICS Inc. (NYSE:PSTV)
Last: | $ |
---|---|
Change Percent: | 2.29% |
Open: | $2.15 |
Close: | $2.23 |
High: | $2.29 |
Low: | $2.15 |
Volume: | 51,911 |
Last Trade Date Time: | 02/12/2020 04:43:17 pm |
News | PLUS THERAPEUTICS Inc. (NYSE:PSTV)
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, toda...
Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an exploratory endpoint in the ReSPECT-LM trials Controlled clinical trial dat...
Message Board Posts | PLUS THERAPEUTICS Inc. (NYSE:PSTV)
Subject | By | Source | When |
---|---|---|---|
The company more than likely will announce a | Sierra20 | investorshub | 04/20/2023 4:52:51 AM |
NEWS -- Plus Therapeutics Completes Enrollment of the | Paulness | investorshub | 04/19/2023 11:51:05 AM |
NEWS -- Plus Therapeutics to Participate in Panel | Paulness | investorshub | 04/19/2023 12:00:25 AM |
NEWS -- Plus Therapeutics Completes Phase 1/Part A | Paulness | investorshub | 04/18/2023 11:33:10 AM |
May announce reverse split on 4/20? | Sierra20 | investorshub | 04/12/2023 1:57:16 PM |
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical compa...
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, toda...
Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an exploratory endpoint in the ReSPECT-LM trials Controlled clinical trial dat...